While the incidence of colorectal cancer (CRC) has dropped significantly among older adults in recent years — a trend attributed to regular screening colonoscopies and lower smoking rates —...

Additional long-term data from the TRiMM-2 study in patients receiving talquetamab and DARZALEX FASPRO® combination biweekly regimen showed an overall response rate of more than 80 percent...

The Janssen Pharmaceutical Companies of Johnson & Johnson announced today the first-ever results from the Phase 1b RedirecTT-1 study of TECVAYLI® (teclistamab-cqyv), a first-in-class BCMAxCD3...

– PRGN-2009 combined with an investigational checkpoint inhibitor resulted in a 30% ORR in patients with heavily pre-treated HPV-associated cancers that were naïve or resistant to checkpoint...

-- Breadth of pipeline featured in multiple early clinical data presentations, reflecting diversity of fundamental growth drivers across development programs -- CAMBRIDGE, Mass., June 3, 2023...